The Food and Drug Administration has issued new interchangeability designations for at least two adalimumab biosimilars in recent days, which ends exclusivity for Alvotech and Teva’s Simlandi for the most-commonly prescribed dose. Last week, Celltrion announced receiving their designation for Yuflyma, and today, Samsung Bioepis and Organon released a press statement indicating that Hadlima was … Continue reading New Adalimumab Interchangeability Designations Announced, Creating a Complex, Confusing Environment